ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials-Reference-Cited by-同舟云学术

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials

Published:2016-03-23 Issue:9 Volume:87 Page:993-999
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Wang Jinping,Logovinsky Veronika,Hendrix Suzanne B,Stanworth Stephanie H,Perdomo Carlos,Xu Lu,Dhadda Shobha,Do Ira,Rabe Martin,Luthman Johan,Cummings Jeffrey,Satlin Andrew

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

BMJ

Subject

Psychiatry and Mental health,Neurology (clinical),Surgery

Reference16 articles.

1. Toward defining the preclinical stages of Alzheimer's disease: recommendations from The National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease;Sperling;Alzheimers Dement,2011

2. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease;Albert;Alzheimers Dement,2011

3. Revising the definition of Alzheimer's disease: a new lexicon;Dubois;Lancet Neurol,2010

4. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives;Hampel;Nat Rev Drug Discov,2010

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic approaches for Alzheimer’s disease: Exploring active and passive vaccine progress;Brain Research;2024-10

2. Predicting Conversion Time from Mild Cognitive Impairment to Dementia with Interval-Censored Models;Journal of Alzheimer's Disease;2024-08-27

3. A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias;Medicine;2024-07-26

4. Use of robust norming to create a sensitive cognitive summary score inde novoParkinson’s disease;2024-07-08

5. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-06-25